NY-ESO-1-derived peptide–MHC complex (NY-ESO-1/MHC)

The NY-ESO-1-derived peptide–MHC complex is a highly specific therapeutic target formed when fragments of the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) protein are presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, typically HLA-A*02:01 (Biomedicines, 2024). NY-ESO-1 is a prominent member of the cancer-testis antigen (CTA) family, characterized by restricted expression in the immune-privileged germ cells of the testis and aberrant overexpression in a wide range of cancers, such as synovial sarcoma, melanoma, and multiple myeloma (PNAS, 2018). This expression pattern makes the NY-ESO-1/MHC complex an ideal target for precision immunotherapy, as it is virtually absent from healthy somatic tissues. Therapeutic strategies targeting this complex include T-cell receptor-engineered T-cell (TCR-T) therapies and TCR-like bispecific antibodies, which are designed to recognize the unique peptide-MHC configuration and trigger a potent cytotoxic T-cell response against the tumor (Nature Medicine, 2023). The clinical utility of this target was recently validated by the FDA approval of afamitresgene autoleucel for synovial sarcoma in August 2024 (FDA, 2024). Effective use of these therapies depends on patient screening for both the presence of the NY-ESO-1 antigen and the specific HLA restriction element required for its presentation. While generally safe due to the restricted expression of NY-ESO-1, potential risks include cytokine release syndrome and off-target cross-reactivity with similar peptides in normal tissues (ClinicalTrials.gov, 2023).

Other names

NY-ESO-1/HLA-A*02:01 complexNY-ESO-1/HLA-A2 complexNY-ESO-1 p157-165/HLA-A*02:01NY-ESO-1/HLA complexpMHC complexNY-ESO-1 peptide-MHC complex

Engineered T-cell receptors (TCRs) or TCR-like antibodies specifically bind to the NY-ESO-1 peptide presented within the MHC groove on the tumor cell surface. This binding event triggers the activation of the effector T cell, leading to the release of perforins and granzymes, which induce apoptosis and lysis of the target tumor cell (Biomedicines, 2024; Nature Medicine, 2023).